CLEC10A and ductal breast carcinoma in situ: Notably, Wang-Johanning et al. discovered that serum HML-2 mRNA was upregulated in women with early-stage ductal carcinoma in situ (DCIS), indicating its potential as an early marker for metastatic risk.